Puma Biotechnology
PBYI
128 hedge funds and large institutions have $366M invested in Puma Biotechnology in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 24 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
18% more capital invested
Capital invested by funds: $309M → $366M (+$57M)
13% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 24
2% more funds holding
Funds holding: 125 → 128 (+3)
4.04% less ownership
Funds ownership: 93.2% → 89.15% (-4%)
43% less call options, than puts
Call options by funds: $2.22M | Put options by funds: $3.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.85M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.79M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$4.66M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$4.61M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.4M |
| 2 |
DM
Deerfield Management
New York
|
-$8.13M |
| 3 |
Millennium Management
New York
|
-$8.03M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.62M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.2M |
PBYI Hedge Fund Activity: Q2 2020 in Review
128 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2020, worth a combined $366M — up 18% from $309M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PBYI positions and 24 closed out — a net gain of 3 holders — while 45 added to existing stakes and 36 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $5.85M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21.4M sold.
- 128 institutional investors held Puma Biotechnology (PBYI) as of Q2 2020, up from 125 in Q1 2020.
- Funds reported $366M of Puma Biotechnology stock for Q2 2020, up 18% quarter-over-quarter.
- 27 funds opened new Puma Biotechnology positions in Q2 2020 and 24 closed out, a net change of +3 holders.
- The largest Puma Biotechnology buyer in Q2 2020 was Tang Capital Management, an estimated $5.85M added.
- The largest Puma Biotechnology seller in Q2 2020 was EcoR1 Capital, an estimated $21.4M sold.
Based on aggregated 13F filings for Q2 2020.